Carthera is a French company whose SonoCloud implant, fitted in the skull after brain tumour surgery, sends ultrasound pulses that briefly open the blood-brain barrier before each chemotherapy dose.
Carthera, founded in 2010 from work at the Pitié-Salpêtrière hospital in Paris, developed the SonoCloud-1 and the larger nine-emitter SonoCloud-9, unfocused ultrasound implants placed in the bone window after tumour resection and activated with intravenous microbubbles to open the blood-brain barrier over a wide region. It has run trials in recurrent glioblastoma with carboplatin and in brain metastases, and is preparing pivotal studies.
Shares Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud), Brain metastases (intracranial disease), Glioma & glioblastoma and the tag machines-wave2.
Shares Glioma & glioblastoma and the tag machines-wave2.
Shares Brain metastases (intracranial disease) and the tag machines-wave2.
Shares Brain metastases (intracranial disease) and the tag machines-wave2.
Shares Glioma & glioblastoma and the tag machines-wave2.
Shares Glioma & glioblastoma and the tag machines-wave2.
Shares Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud), Focused-ultrasound blood-brain barrier opening.
Shares Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud), Focused-ultrasound blood-brain barrier opening, Glioma & glioblastoma.